

Jonathan Vogelgsang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2072684/publications.pdf>

Version: 2024-02-01

21
papers

1,098
citations

840776

11
h-index

713466

21
g-index

25
all docs

25
docs citations

25
times ranked

1000
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection and quantification of A β 1-40 (APP669-711) in cerebrospinal fluid. <i>Journal of Neurochemistry</i> , 2022, 160, 578-589.	3.9	6
2	Novel Exosome Biomarker Candidates for Alzheimer's Disease Unravelled Through Mass Spectrometry Analysis. <i>Molecular Neurobiology</i> , 2022, 59, 2838-2854.	4.0	13
3	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	21.4	700
4	Identification of risk factors for delirium, cognitive decline, and dementia after cardiac surgery (FINDERI-find delirium risk factors): a study protocol of a prospective observational study. <i>BMC Cardiovascular Disorders</i> , 2022, 22, .	1.7	4
5	Exosomal A β -Binding Proteins Identified by ∞ In Silico Analysis Represent Putative Blood-Derived Biomarker Candidates for Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3933.	4.1	12
6	Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 94.	6.2	12
7	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	12.8	140
8	Current clinical practice of electroconvulsive therapy and repetitive transcranial magnetic stimulation in psychiatry, a German sample. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 181-190.	3.2	4
9	Prevalence of affective disorders and dementia in inflammatory polyarthropathies. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 247-252.	3.2	0
10	Nuclear medical imaging as part of dementia diagnostics in psychiatric day-care clinics and inpatient care settings. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 809-815.	2.9	0
11	Development and Technical Validation of an Immunoassay for the Detection of APP669-711 (A β 1-40) in Biological Samples. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6564.	4.1	12
12	Pre-Analytical Sampling and Storage Conditions of Amyloid- β Peptides in Venous and Capillary Blood. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 529-535.	2.6	11
13	Potential of FTIR Spectroscopy Applied to Exosomes for Alzheimer's Disease Discrimination: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 391-405.	2.6	27
14	Higher Level of Mismatch in ϵ APOE ϵ 4 Carriers for Amyloid-Beta Peptide Alzheimer's Disease Biomarkers in Cerebrospinal Fluid. <i>ASN Neuro</i> , 2019, 11, 175909141984552.	2.7	10
15	Comparison between amyloid-PET and CSF amyloid- β biomarkers in a clinical cohort with memory deficits. <i>Clinica Chimica Acta</i> , 2019, 492, 62-68.	1.1	20
16	Validation of a prototype tau Thr231 phosphorylation CSF ELISA as a potential biomarker for Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2019, 126, 339-348.	2.8	16
17	Multiplex immunoassay measurement of amyloid- β 42 to amyloid- β 40 ratio in plasma discriminates between dementia due to Alzheimer's disease and dementia not due to Alzheimer's disease. <i>Experimental Brain Research</i> , 2018, 236, 1241-1250.	1.5	28
18	A two-step immunoassay for the simultaneous assessment of A β 1-38, A β 1-40 and A β 1-42 in human blood plasma supports the A β 1-42/A β 1-40 ratio as a promising biomarker candidate of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 121.	6.2	39

#	ARTICLE	IF	CITATIONS
19	Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 87.	6.2	13
20	Cardiovascular and metabolic comorbidities in patients with Alzheimer's disease and vascular dementia compared to a psychiatric control cohort. <i>Psychogeriatrics</i> , 2018, 18, 393-401.	1.2	13
21	Reproducibility of Alzheimer's Disease Cerebrospinal Fluid-Biomarker Measurements under Clinical Routine Conditions. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 203-212.	2.6	14